An Old Drug Gets a Modern Test
Digoxin has been part of cardiovascular medicine for generations, but its role in contemporary heart failure care has remained unsettled. A newly published randomized controlled trial in Nature Medicine puts that question back into focus with a large, placebo-controlled test of low-dose digoxin in patients with symptomatic chronic heart failure and a left ventricular ejection fraction of 50% or less.
The study, known as the DECISION trial, enrolled 1,001 patients and randomized them to either low-dose digoxin or placebo. Investigators targeted serum digoxin concentrations of 0.5 to 0.9 ng/ml, a range meant to preserve potential benefit while limiting toxicity concerns that have long shadowed the drug. Participants had a mean age of 72 years, 28% were women and 29% had atrial fibrillation.
The topline result was mixed. Over a median follow-up of 36.5 months, the trial did not show a statistically significant reduction in its primary composite outcome: total worsening heart failure events, defined as total hospitalizations or urgent hospital visits for worsening heart failure, plus cardiovascular mortality. That means the study did not deliver the kind of clear positive result that would immediately reset guidelines or practice.
Still, the numbers did not point toward failure in a simple sense. Event counts were lower in the digoxin group than in the placebo group, suggesting a possible clinical signal that stopped short of conventional statistical significance.
What the Trial Found
In the digoxin group, 238 primary-outcome events occurred in 131 of 500 patients. In the placebo group, 291 primary-outcome events occurred in 152 of 501 patients. That translated to a rate ratio of 0.81, with a 95% confidence interval of 0.61 to 1.07 and a P value of 0.133.
On the narrower count of worsening heart failure events alone, the totals were 155 in the digoxin arm and 203 in the placebo arm, corresponding to a rate ratio of 0.76 with a 95% confidence interval of 0.54 to 1.05. Cardiovascular mortality was similar between groups: 83 patients, or 17%, in the digoxin group and 88 patients, or 18%, in the placebo group, with a hazard ratio of 0.93.
Those figures matter because they show the study was not negative across every measure in a directional sense. Instead, it produced a recurring pattern of somewhat fewer events in patients receiving digoxin, without crossing the statistical threshold for the primary endpoint. For clinicians and researchers, that puts the result into a familiar but consequential category: not definitive, but difficult to dismiss.
It also underscores why digoxin has remained controversial. The drug is inexpensive and widely known, and earlier studies suggested it might offer benefit, especially in reducing hospitalizations. Yet uncertainty about safety, the evolution of heart failure therapy and the lack of modern randomized evidence have kept it from regaining a secure place in standard regimens.
Why This Result Matters Now
Heart failure treatment has changed dramatically over the past two decades. Patients now often receive layered, guideline-directed therapy that can include multiple drug classes, each aimed at improving symptoms, reducing hospitalization and extending survival. In that context, any older therapy has to prove its value against a much stronger background standard of care than it faced in earlier eras.
That is what makes the DECISION trial notable. It did not test digoxin as a historical artifact. It tested low-dose digoxin in a modern randomized framework and asked whether it still adds measurable value. The answer, based on the primary outcome, is that the benefit was not proven. But the directional reduction in worsening heart failure events suggests the door remains open to more targeted interpretation.
One practical reading is that low-dose digoxin may still have relevance for some patients if future work can define where the signal is strongest. Another is that the drug’s effect, if real, may be modest enough that even a well-run trial has trouble separating it clearly from background therapy and patient variability.
Either way, the trial helps move the discussion out of the realm of anecdote and legacy habit. It gives the field a substantial modern data set instead of relying mainly on older evidence and retrospective arguments.
What Comes Next for Digoxin
The new findings are unlikely to trigger a broad revival of digoxin for all patients with heart failure and reduced or mildly reduced ejection fraction. The primary endpoint was not met, and that fact will dominate any evidence-based interpretation. But the study also does not support writing the drug off as irrelevant.
Because event totals trended lower in the digoxin arm, the most likely next step is more selective analysis: which patients, under what conditions, might be more likely to benefit from low-dose treatment? The published abstract does not claim such an answer, but it sets up the question more clearly than before.
That question matters beyond digoxin itself. Health systems continue to look for therapies that can reduce hospitalizations in chronic heart failure, especially when they are inexpensive and already familiar to clinicians. A modestly effective drug can still matter if it is safe, practical and targeted appropriately.
The DECISION trial therefore lands as neither a vindication nor a rejection. It is a disciplined recalibration. Digoxin, one of the oldest drugs in the field, has now faced a modern randomized test and emerged with a result that is clinically suggestive but statistically inconclusive.
For now, that means restraint. The evidence does not justify sweeping claims that low-dose digoxin should return to routine use across the board. But it also leaves enough signal to ensure the conversation is not over. In heart failure care, where reducing worsening episodes remains a central goal, even an old therapy can still earn a second look if the data warrant it.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
